Literature DB >> 3794713

Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury.

C A Altar, M R Marien, J F Marshall.   

Abstract

Alterations in neostriatal dopamine metabolism, release, and biosynthesis were determined 3, 5, or 18 days following partial, unilateral destruction of the rat nigrostriatal dopamine projection. Concentrations of dopamine and each of its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 3-methoxytyramine (3-MT) were markedly decreased in the lesioned striata at 3, 5, or 18 days postoperation. The decline in striatal high-affinity [3H]dopamine uptake closely matched the depletion of dopamine at 3 and 18 days postoperation. However, neither DOPAC, HVA, nor 3-MT concentrations were decreased to as great an extent as dopamine at any time following lesions that depleted the dopamine innervation of the striatum by greater than 80%. In these more severely lesioned animals, dopamine metabolism, estimated from the ratio of DOPAC or HVA to dopamine, was increased two- to four-fold in the injured hemisphere compared with the intact hemisphere. Dopamine release, estimated by the ratio of 3-MT to dopamine, was more increased, by five- to sixfold. Importantly, the HVA/dopamine, DOPAC/dopamine, and 3-MT/dopamine ratios did not differ between 3 and 18 days postlesioning. The rate of in vivo dopamine biosynthesis, as estimated by striatal DOPA accumulation following 3,4-dihydroxyphenylalanine (DOPA) decarboxylase inhibition with NSD 1015, was increased by 2.6- to 2.7-fold in the surviving dopamine terminals but again equally at 3 and 18 days postoperation. Thus, maximal increases in dopamine metabolism, release, and biosynthesis occur rapidly within neostriatal terminals that survive a lesion. This mobilization of dopaminergic function could contribute to the recovery from the behavioral deficits of partial denervation by increasing the availability of dopamine to neostriatal dopamine receptors. However, these presynaptic compensations are not sufficient to account for the protracted (at least 3-week) time course of sensorimotor recovery that has been observed following partial nigrostriatal lesion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3794713     DOI: 10.1111/j.1471-4159.1987.tb04106.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Distribution of dopamine, its metabolites, and D1 and D2 receptors in heterozygous and homozygous weaver mutant mice.

Authors:  T A Reader; A R Ase; C Hébert; F Amdiss
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

2.  L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.

Authors:  K Xu; D E Dluzen
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression.

Authors:  J L Labandeira-Garcia; G Rozas; E Lopez-Martin; I Liste; M J Guerra
Journal:  Exp Brain Res       Date:  1996-02       Impact factor: 1.972

4.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

5.  Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

Authors:  M B Spina; G Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

6.  Intranigral dopamine toxicity and alpha-synuclein response in rats.

Authors:  Cristina Gómez-Santos; Pol Giménez-Xavier; Isidre Ferrer; Santiago Ambrosio
Journal:  Neurochem Res       Date:  2006-06-28       Impact factor: 3.996

7.  Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease.

Authors:  Marcela Ferreira Cordellini; Giovana Piazzetta; Karin Cristine Pinto; Ana Márcia Delattre; Francesca Matheussi; Ruither O G Carolino; Raphael Escorsim Szawka; Janete A Anselmo-Franci; Anete Curte Ferraz
Journal:  Neurochem Res       Date:  2011-02-24       Impact factor: 3.996

Review 8.  Synaptic protein alterations in Parkinson's disease.

Authors:  Ilse S Pienaar; David Burn; Christopher Morris; David Dexter
Journal:  Mol Neurobiol       Date:  2011-12-29       Impact factor: 5.590

9.  Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease.

Authors:  Asya Ozkizilcik; Aruna Sharma; Dafin F Muresanu; José V Lafuente; Z Ryan Tian; Ranjana Patnaik; Herbert Mössler; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

10.  Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.

Authors:  S Sarre; N De Klippel; P Herregodts; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.